---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-22-000033"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2022-10-03T23:59:59+00:00"
generated_at: "2026-06-23T05:57:17.328264+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Skye shareholders approve acquisition of Emerald Health; Phase 1 trial imminent

## Summary
- 97% of votes cast (excluding affiliates) approved the acquisition of Emerald Health Therapeutics.
- Expected closing before October 15, subject to Canadian Securities Exchange listing approval.
- Phase 1 trial of SBI-100 in glaucoma to start in Australia; first dosing expected in November 2022.
- Final manufacturing step is quality testing; drug product expected to be available in October 2022.
- Auditor changed from Friedman LLP to Marcum LLP following merger; no disagreements reported.

## SEC filing metadata
- accession: 0001516551-22-000033
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2022-10-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.01, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655122000033/0001516551-22-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655122000033/skye-20220929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-22-000033
- JSON: https://secwatch.observer/filing/0001516551-22-000033.json
- Plain text: https://secwatch.observer/filing/0001516551-22-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.